BACKGROUND: Treatment options for non-small cell lung cancer (NSCLC) patients lacking actionable genetic alterations (non-AGA) remain limited, particularly after first-line (1 L) therapy. This study evaluated real-world treatment patterns and outcomes among second or later-line (2 L+) patients with non-AGA nonsquamous (NSQ) metastatic NSCLC (mNSCLC) at a Health Maintenance Organization in Israel. METHODS: A retrospective cohort study used the Maccabi Healthcare Services database to identify 2 L+ adult patients with non-AGA NSQ mNSCLC between January 2017 and December 2020. Outcomes included progression-free survival (PFS), overall survival (OS), and time-to-next-treatment or death (TTNTD), analyzed using descriptive statistics and Kaplan-Meier methodology. RESULTS: = 74, 42.0%) following 1 L chemotherapy. Median overall TTNTD from 2 L initiation was 3.73 months (docetaxel: 1.78 months; anti-PD-L1 combination: 7.05 months). Median overall PFS was 2.56 months (docetaxel: 1.78 months; anti-PD-L1 combination: 9.48 months) and median overall OS was 5.51 months (docetaxel: 1.81 months; anti-PD-L1 combination: 9.48 months). CONCLUSIONS: These findings highlight the high unmet need among 2 L+ non-AGA NSQ mNSCLC patients in Israel.
Moser et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: